Table 2 Patient characteristics.

From: Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers

VariablesPD-L1PD-L2
Negative N = 368Positive N = 69P valueNegative N = 366Positive N = 71P value
Age (y), mean ± SD65.9 ± 9.067.4 ± 9.00.9066.5 ± 9.064.3 ± 8.80.029
Sex  0.39  0.65
  Male328 (89.1)59 (85.5) 323 (88.3)64 (90.1) 
  Female40 (10.9)10 (14.5) 43 (11.8)7 (9.9) 
Body mass index, mean ± SD21.8 ± 3.021.5 ± 3.30.5021.7 ± 3.121.8 ± 3.10.72
Tobacco use  0.013  0.41
  Yes316 (85.9)51 (73.9) 305 (83.3)62 (87.3) 
  No52 (14.1)18 (26.1) 61 (16.7)9 (12.7) 
Alcohol use  0.10  0.46
  Yes325 (88.3)56 (81.2) 321 (87.7)60 (84.5) 
  No43 (11.7)13 (18.8) 45 (12.3)11 (15.5) 
Comorbidity  0.23  0.70
  Present262 (71.2)54 (78.3) 266 (72.7)50 (780.4) 
  Absent106 (28.8)15 (21.7) 100 (27.3)21 (29.6) 
Histological type  0.32  0.86
  Squamous cell carcinoma319 (86.7)64 (92.8) 322 (88.0)61 (85.9) 
  Adenocarcinoma32 (8.7)4 (5.8) 29 (7.9)7 (9.9) 
  Others17 (4.6)1 (1.5) 15 (4.1)3 (4.2) 
Location  0.64  0.29
  Upper59 (16.0)8 (11.6) 54 (14.8)13 (18.3) 
  Middle171 (46.5)34 (49.3) 168 (45.9)37 (52.1) 
  Lower138 (37.5)27 (39.1) 144 (39.3)21 (29.6) 
pStage  0.001  0.94
  I159 (43.2)14 (20.3) 145 (39.6)28 (39.4) 
  II97 (26.4)19 (27.5) 99 (27.1)17 (23.9) 
  III10 (27.2)32 (46.4) 109 (29.8)23 (32.4) 
  IV12 (3.3)4 (5.8) 13 (3.6)3 (4.2) 
Preoperative therapy  0.015  0.81
  Present125 (34.0)34 (49.3) 134 (36.6)25 (35.2) 
  Absent243 (66.0)35 (50.7) 232 (63.4)46 (64.8) 
Tumour-infiltrating lymphocytes (at the invasive margin)  0.030  0.42
  Absent8 (2.2)0 (0) 7 (1.9)1 (1.4) 
  Mild121 (32.9)18 (26.1) 119 (32.5)20 (28.2) 
  Moderate171 (46.5)28 (40.6) 169 (46.2)30 (42.3) 
  Strong68 (18.5)23 (33.3) 71 (19.4)20 (28.2) 
  1. PD-L1 programmed death ligand 1, PD-L2 programmed death ligand 2.